Bristol Taxol Three-Hour Infusion Patent Not Novel - U.K. Patents Court
Executive Summary
The public dissemination of safety data from Phase I and Phase II trials of Bristol-Myers Squibb's Taxol (paclitaxel) render the company's three-hour infusion patent for the oncologic drug "obvious," a U.K. patent court has ruled.